Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Investors were disappointed with Victoza’s CV data earlier this year – but were clearly more upbeat about the results from semaglutide in the SUSTAIN trial. Novo Nordisk’s shares ticked up ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

A new study shows that semaglutide can improve glucose levels for people with type 1 diabetes who use automated pumps, without increasing hypoglycemia. In this double-blinded randomized trial ...

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product ... in a 2023–24 randomized clinical trial backed by Lilly.

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...

Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...